InflaRx N.V. (IFRX), Tuesday announced updates regarding its Phase 3 study for vilobelimab in pyoderma gangrenosum, which was terminated earlier this year after an Independent Data Monitoring Committee recommended the trial be stopped early due to futility.
The recently announced in-depth data analysis reveals the treatment's efficacy, particularly regarding ulcer volume reduction, which further supports the potential role of the C5a/C5aR pathway in certain neutrophilic skin diseases.
The company noted that the primary clinical endpoint of complete target ulcer closure on two consecutive visits showed a difference in favor of vilobelimab over placebo of 20.8 percent versus 16.7 percent.
Meanwhile, key secondary endpoints such as complete disease remission showed improvement in favor of vilobelimab over placebo.
The company expects to have a meeting with the FDA to discuss a potential path forward for vilobelimab.
In the pre-market hours, IFRX is moving down 3.93 percent, to $0.97 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Health News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.